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Available online 27 March 2020Hyperthermia therapy is a potent enhancer of chemotherapy and radiotherapy. In particular, microwave (MW)
and radiofrequency (RF) hyperthermia devices provide a variety of heating approaches that can treat most can-
cers regardless the size. This review introduces the physics of MW/RF hyperthermia, the current state-of-the-art
systems for both localized and regional heating, and recent advancements in hyperthermia treatment guidance
using real-time computational simulations and magnetic resonance thermometry. Clinical trials involving
RF/MW hyperthermia as adjuvant for chemotherapy are also presented per anatomical site. These studies
favor the use of adjuvant hyperthermia since it significantly improves curative and palliative clinical outcomes.
The main challenge of hyperthermia is the distribution of state-of-the-art heating systems. Nevertheless, we
anticipate that recent technology advanceswill expand the use of hyperthermia to chemotherapy centers for en-
hanced drug delivery. These new technologies hold great promise not only for (image-guided) perfusion modu-
lation and sensitization for cytotoxic drugs, but also for local delivery of various compounds using
thermosensitive liposomes.
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Despite progress in cancer treatment outcomes, cancer mortality
rates are rising because society faces an aging population. Patients that
do survive after treatment, suffer longer from the severe side-effects in-
duced by current aggressive treatments that often include radiotherapy,
chemotherapy, or both. Hence, improvement of cancer therapy effec-
tiveness is required while simultaneously reducing long-term side-
effects. Extensive biologic research showed that hyperthermia therapy
(HT) is a potent sensitizer of ionizing radiation and that HT can also
greatly enhance the effectiveness of chemotherapy [1,2] as well as in-
crease the tumor-specific immune surveillance [3,4]. Clinically, the ben-
eficial impact of HT induced by radiofrequency (RF) electromagnetic
waves was demonstrated by many phase III trials for several tumor
sites when combined with ionizing radiation [5] and a number of che-
motherapeutics [6–9]. Of relevance, no increase in late toxicity induced
byHTwas found in these studies,making heat a potent enhancer of cur-
rent cancer treatments without adding to their long-term side effects.
Although clinical work to date has demonstrated only temperature
dose-effect relations [10], biological work also showed the impact of
heat-mediated perfusion modulation on therapy outcome [11]. In addi-
tion, HT is being studied for enhanced local drug delivery by heat-
mediated release of drugs encapsulated in thermosensitive liposomes
[12,13]. These are important incentives to combineHTwith chemother-
apy, especially via controlled localized heating that can be achieved
with electromagnetic-based methods such as radiofrequency (RF) and
microwave (MW). Recent developments in RF/MW HT device technol-
ogy are enabling significantlymore localized application of HT, but a de-
tailed review is currently not available.
This review summarizes the current clinical status, recent develop-
ments and potential of RF and MW induced heating aimed at its utility
in local drug delivery. It first reviews the basic principles, strengths
and limitations of RF andMW, continues with all clinical studies per an-
atomical site involving RF/MW HT as adjuvant for chemotherapy, re-
views the potential of new RF/MW technologies entering the clinic
andfinalizeswith a future outlook. The review is kept broad as to enable
comprehensive assessment of the field by medical doctors, basic re-
searchers, physicists, and engineers. Further, it is designed for both
newcomers in thefield aswell asmore established researchers and clin-
ical personnel.
2. Physics of radiofrequency andmicrowavemediated hyperthermia
2.1. Aim of hyperthermia
The goal of HT is to raise temperature in tumors to render the cells
more sensitive to ionizing radiation and chemotherapy [14,15]. The
proven effectiveness of HT relies on its thermal effect on tumors that
is dependent on both temperature and heating time, as shown by pre-
clinical [16–18] and clinical studies [19–23]. The sensitization occurs
mostly via increased blood perfusion, increased oxygenation, inhibition
of radiation-induced DNA damage repair, and boosting local/systemic
immune response [24].
The range of the therapeutic temperature goal in tumors differs in
literature and treatment protocols by a few degrees centigrade, butspan within 39–45 °C [5]. The difference is explained with evolving
knowledge of HT effects, but also depends on the type of combination
with other therapeutic agents and location in the body. The suggestion
of an expert panel at ESHO 20181 defined the goal temperatures to be
40–44 °C, which has now been widely accepted. This temperature
range is nevertheless based on a strong evidence coming from clinical
studies that combines HT with radiotherapy and can be slightly lower
for the protocols combining HT with chemotherapy, i.e., 39–43 °C [5].
This range is related to increases in perfusion found at 39 °C and the
finding that temperatures greater than 43 °C increase the risk for vascu-
lar damage [25], which will reduce the amount of drug that can be de-
livered to the tumor. It should be emphasized that a benefit of HT has
been clinically demonstrated only when applied in combination with
chemotherapy and/or radiotherapy [5,6]. In current practice, HT is ap-
plied for 60 min before/after radiotherapy within a 0.5–4 h window,
while with chemotherapy, HT is applied simultaneously or shortly
after the chemotherapeutic regimen [14]. Section 3 of this review pro-
vides an in-depth analysis of the clinical trials to date involving heat
and chemotherapy.
2.2. Heating by RF and mw
Many different electromagnetic (EM)-based technologies have been
used to applyHT. Theirmain difference is the applicator frequency: 3Hz
to 300 MHz (RF), 300 MHz to 300 GHz (MW), and 300 GHz–430 THz
(infrared, IR). This chapter will cover the RF/MW devices and their use
in clinical trials, where the transition from RF to MW is defined to be
at 300 MHz.
When applying RF/MW energy in the human body, all tissues be-
have as lossy dielectrics, i.e., they are both poor insulators and poor
electrical conductors. The tissue heating mechanism varies with fre-
quency of the EM wave. At RF below approximately 30 MHz a pro-
cess known as joule heating occurs as a result of ion movement
due to applied EM field, causing energy dissipation by friction and
collision with surrounding molecules, leading to local heating of
tissue.
The radiative mode of EM propagation and dielectric losses in tissue
come into being predominant at frequencies above 100MHz. Heating is
generated primarily by mechanical frictions between adjacent polar
water molecules, which oscillate 100 million cycles per second in the
time varying electric field.
The interaction of RF/MW fields with biological tissue is typically
investigated using a macroscopic model including the dielectric prop-
erties: effective electrical conductivity σ (units of S/m) and relative
permittivity εr (unitless). The effective electrical conductivity em-
bodies all electrical losses in the material due to the currents driven
by the EM field. The relative permittivity describes the ability to po-
larize a material subjected to an applied EM field. Both properties are
tissue, frequency and temperature dependent [26–28] and can be
modeled mathematically using empirical data [29,30]. An overview
of normal human dielectric properties was originally measured and
tabulated by Gabriel et al. [30]. A more comprehensive database
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in the IT'IS Tissue Properties Database [31].
The EM energy is converted into heat through the lossy nature of the
tissue. The energy absorbed in tissue is often described by the Specific
Absorption Rate (SAR) with units of W/kg. The SAR parameter corre-
sponds to the rate atwhich EMenergy is absorbed per unitweight of tis-
sue, and can be calculated using either of the two equations:




SAR ¼ CpdTdt ð2Þ
where ρ is the mass density (kg/m3), E is the magnitude of the local
electric field (V/m), Cp is the specific heat capacity (J/kg/°C) of the tissue
and dT/dt is the initial heating rate (°C/s). The right-hand side of Eq. 2
suggests the relation of SAR and initial temperature rise in tissue
when thermal conduction and thermal convection effects are neglected.
As an example, to increase the temperature of muscle tissue by 1 °C in 1
min, an average SAR of 60W/kg is required [32]. Tomodel a heat trans-
port in the human body in the treatment planning phase, the Pennes
bioheat transfer equation is commonly applied [33]. However, neither
heat exchange between tissue and realistic vasculature, or for the direc-
tion of blood flow is accounted in this straightforward model. The most
accurate calculations are thus performed by modelling of the vascula-
ture discretely, also known as a discrete vasculature (DIVA) model
[34]. At themoment, themain hurdle for DIVAmodelling is the inability
to discriminate vessels down to the required 0.1 mm diameter using
current imaging modalities in a clinically realistic time [35,36]. Hence,
currently the PBHE ismostly useddue to its simplicity and validity in tis-
sues with small (b 0.1 mm in diameter) blood vessels.
In order to quantify the hyperthermic effect reported in different
studies and to assure treatment reproducibility, a relationship between
thermal exposure and thermal damage has been defined. In a proposed
thermal-dose relationship, often referred to as thermal isoeffect dose
(TID) or cumulative equivalent minutes at 43 °C (CEM43) [15,37,38],
it was shown that for every 1 °C rise in temperature above 43 °C, cell
killing doubles while cell killing diminishes by about one quarter for
every 1 °C below 43C. In order to reflect the limited information about
the spatial and timedistribution of the achieved temperatures in treated
area as provided by the current thermometry, a treatment descriptor
has been modified to consider the 10th percentile of the temperature
distribution (T90). The current expression CEM43T90 thus compares
different tissues in terms of their thermal-dose sensitivity is a combina-
tion of CEM43with a threshold temperature T90. An alternative thermal
dose parameter is TRISE, which is based on the temperature exceeded
by 50% of measurement points and duration of heating [22]. All the
above parameters display some conceptual weaknesses as they repre-
sent the effect of the entire history of heat exposure on cell death, but
they do not include the radio- or chemo-sensitization effect [10]. None-
theless, there is a strong correlation between thermal dose and clinical
outcomes as has been shown by several clinical studies [23,39–41].
Thus, in order to achieve optimal therapeutic results, adequate temper-
ature must be delivered for an appropriate period of time to the entire
tumor volume. Therefore, and despite some limitations in capturing
the full hyperthermic effect, CEM43 and TRISE have been identified as
two of the most important measures of the treatment efficacy when
combining radiation with HT to treat cancer [10]. This correlative effect
is expected, but not yet validated, in thermochemotherapy treatments.
Details about the thermal dose concept are given in the reference [42]
of this issue.2.3. Different techniques to induce localized heating
A summary of different techniques to apply HT is given in Table 1 and
is complemented by Table 2, which lists all HT applicators that are com-
mercially available and have been used in clinical thermochemotherapy
trials.
2.3.1. Superficial hyperthermia
Localized heating of superficial tumors has been the largest clinical
application of HT to date, owing to the accessibility for heating devices,
thermometry and clinical observation. However, it has been used prev-
alently in protocols that combine HT with RT.
In general, superficial heating devices apply energy to heat a limited
volume of tissue close to theheatingdevice. Power deposition decreases
exponentially as radio/microwaves penetrate through tissue. In general,
higherMW frequencies provide localized heating of skin and superficial
tissues, while the lower frequencies will heat larger and deeper regions
in the body. The penetration depth from the skin surface, often defined
in HT as half-power depth, is 10 cm at around 10 MHz. Superficial
heating within 2–4 cm from the skin can be obtained by applying fre-
quencies in the range of 400–1000 MHz.
The EM energy is directed to the treated volume by applicators
placed on the surface with a water bolus, which provides EM coupling
between the applicator and the body. The water in the bolus is circu-
lated at a controlled temperature [45,46], thus protecting the skin
from potential burns. Based on the MW frequency, often 434 or 915
MHz, the typical thermal penetration depth is 3 cmbut can be increased
to a maximum of 4 cm (at 434 MHz) by lowering the water bolus tem-
perature [46]. Furthermore, it is important to be aware that large appli-
cators achieve better penetration depth than small applicators
operating at the same frequency. Covering of large tumors by desired
thermal dose can be achieved by combining of several applicators into
multi-element arrays where power output of each element can be con-
trolled independently. As suggested in Table 2, EM applicators can be
categorized in three classes: waveguide, microstrip, and electrode-
based applicators. A more in-depth overview of the operating princi-
ples, strengths and weaknesses of superficial heating systems is given
in [47], while more detailed description is provided by several reviews
[48–50] and a dosimetric analysis for radiative and capacitive is given
in [51].
2.3.2. Deep hyperthermia - external heating
An effective HT treatment aims to concentrate heat in the tumor
area, while sparing surrounding healthy tissue from temperatures of
43–45 °C [52,53]. Beyond approximately 2 cm from the skin, the tem-
perature goal is often better achieved with a phased-array approach,
where an array of antennas is placed around the patient. The antennas
are then suitably fed in amplitude and phase to create a constructive
wave interference to selectively heat the target region. For all EM
waves, a circumferential array is the optimum arrangement since this
maximizes the interference of the transversewaves, i.e. with the electric
field component of the EMwave oriented along the patient-axis (Fig. 1).
The steering parameters of phased-arrays include the amplitude,
0phase and frequency of the antennas, which are optimized during
treatment planning as discussed in section 4 and reviewed in references
[54, 55].
The operating frequency is a critical parameter in a phased-array
system. At first, it determines the penetration depth that is achievable
with a certain system. Second, it also determines the size of the temper-
ature focal spot, which is approximately one half of the wavelength. For
thepractical range of frequencies used inHT, thewavelengths in soft tis-
sue vary from about 4.5 cm at 1000 MHz up to 2 m at the lower 1 MHz
frequencies. The spatial resolution of higher frequencies can be achieved
by increasing the number of antennas within the applicator, which
Table 1
Summary of electromagnetic-based hyperthermia techniques for cancer treatment.
Heating approach Heating region Typical frequency (f) & number
of Antennas
Typical therapeutic heat focus (region at
40–44 °C)
External Whole body Regional f = 200–375 GHz Whole body
(38.5–40.5 °C for N3 h or 40.5–42 °C
for1–2 h [43,44])
Superficial Local (near the
surface)
f = 400–1000 MHz
one applicator (single or
multi-antenna)
Block-shaped: footprint typically 10 × 10
cm2
Volume: 200–400 cm3
f = 400–1000 MHz
Combination of multiple
applicators
Block-shaped: footprint typically 20 × 30
cm2;
Volume: 120S0–2400 cm3
Deep Regional f ≤ 100 MHz
4 antennas/channels
Heat focus steering in radial
direction
Ellipsoidal shape: 15–20 cm in the main
(patient) axis
Volume:1750–4000 cm3
Locoregional f = 100–300 MHz,
4–12 antennas/channels
Heat focus steering in radial and
axial direction
Ellipsoidal shape: 8–15 cm in the main
(patient) axis
Volume: 250–1750 cm3
Local f = 300–1000 MHz
12 ≤ antennas/channels
Heat focus steering in radial and
axial direction
Ellipsoidal shape: 1.5–8 cm in the main
(patient) axis
Volume: 15–250 cm3





Local f = 27, 434, 915 MHz
1 antenna
Volume: 5–30 cm3
in case of bladder cancer, the complete
400-600 ml volume
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tennas further improves both penetration depth and the steering capa-
bilities of the applicator. As shown in Table 2, the most common
applicator is a phased-array system based on dipole or waveguide an-
tennas. However, smaller alternatives such as the patch [56–58] or
bow-tie [59,60] antennas are being utilized in yet uncommercialized
devices.
Another approach to achieve heating at depth is to utilize capacitive
systems. In this approach, the patient is positioned on a treatment bed
with an embedded electrode while another electrode is placed on the
patient. The electrodes connected to a high-power RF generator work-
ing at frequencies 8–40MHz [61]. Theheatingpattern can bemodulated
installing electrodes with different dimensions, where the heating will
be concentrated near the smaller electrode by concentrating the electric
currents. When applying RF-capacitive heating, an important factor to
consider is unintentional preferential heating of subcutaneous fat. Ded-
icated vigorous cooling strategies are being applied to enable heating
beyond the fat [62].
The first, pioneering studies in semi-deep regions were performed
with capacitive systems as those were believed the only ones to deliver
effective proportion of energy in depth, were affordable and rather
straightforward to use. The introduction of smaller antennas serving
as applicator elements along with advances in treatment planning led
to increased use of radiative systems, especially in Western countries.A number of simulation studies that studied differences in heating char-
acteristics between capacitive and radiative systems and effect of these
differences on heating quality has been recently performed and pub-
lished [51,63]. A representative temperature distributions achieved
with the two distinct techniques are shown in Fig. 2.2.3.3. Deep hyperthermia – internal heating
Internal heating can be achieved via interstitial, intraluminal or
intracavitary RF/MW applicators, which apply energy within a lim-
ited volume of tissue close to the heating device(s). Interstitial HT
is often used in combination with brachytherapy; it uses a needle-
shaped antenna/electrode that is either implanted directly in tissue
or inserted in catheters that are implanted into the target volume.
Due to steep radial fall-off of energy is heating limited to radius of
5–10 mm from the applicator. Interstitial heating thus requires use
of multiple applicators. Intraluminal and intracavitary techniques
utilize the same heating concepts, but applicators are placed within
tubular organs like esophagus and urethra (intraluminal) or natural
body cavities like bladder or cervix (intracavitary). There is a high va-
riety in applicator designs, ranging fromMW antennas, capacitively-
coupled RF catheter-based electrodes, resistively-coupled RF local
current field electrodes, ultrasound systems, as well as hot source
techniques. A more in-depth overview of operating principles of
Table 2
List ofMW/RF commercialmedical devices used in clinical trials that combined adjuvant hyperthermiawith chemotherapy. The references listed are the ones that best explain thephysical
principles of each MW/RF device.
Device Manufacturer, country Applicator Array description HT delivery Frequency
(MHz)
Monitoring References











Alba ON4000 Alfa, Beta,
Gamma, Delta









BSD-500 Pyrexar Medical, US MA-151,
MA-100,
MA-120
1 rectangular waveguide External
Superficial
Local









MA-251 1–24 dipole antenna






















BSD-2000 3D Σ-Eye 3 rings with 4 dipole









1 or 3 rings with 4 dipole








Synergo® RITE Medical Enterprises, NL SB-TS 101 1 half wavelength not





915 3 thermocouples [96]





915 Up to 18 N/A
3 circular models Intracavitary
Deep
Local




3 circular models Intracavitary
Deep
Local



















8 5 thermocouples [61]
HY7000 Nanjing Greathope Co.,
Nanjing, CN











Morestep Science & Technology
Development Co., Ltd.,
Changchun, CN
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clinical devices and their comparison is given in [67].2.3.4. Applicator selection
Due to the strong correlation between applied thermal dose and
therapeutic outcome, adequate temperature must be delivered for an
appropriate period of time (approximately 60 min) to the entiretumor volume. Therefore, heating devices must be technically capable
to deliver the required/planned thermal dose into the specified target
volume, while minimizing heating of the surrounding healthy tissues.
Based on the specific target volume and location, an appropriate heating
technique from Table 1 in combinationwith the listed critical points can
be selected as the first step to plan a treatment. Nevertheless, various
RF/MW systems have unique characteristics, benefits and limitations
that need to be further considered. The recent ESHO Quality Assurance
Fig. 1. Example of two RF hyperthermia systems: radiative-based BSD-2000 3D/MR courtesy of Pyrexar Medical, USA (left); and capacitive-based Thermotron RF-8EX courtesy of
Yamamoto Vinita, Japan.
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help the user to identify clinical conditions where a particular heating
device can be used. Critical points for applicator selection are:
1) Tumor depth below the tissue surface –Due to exponential decrease
of power deposition, the applicator selection is strongly dependent
on the tumor depth. For tumors located deeper than 3–4 cm,
phased-array applicators should be used but the penetration depth
of the radio/microwaves determines the selection of the working
frequency even in this situation. The frequencies applied clinically
are in the range 70 to 140 MHz for tumors located in the pelvic re-
gion [70], and 434 MHz for head and neck region [71]. Devices
using internal RF/MW sources can be used if suitable. Treatment
planning tools can be valuable to find the most appropriate tech-
nique [72].Fig. 2. Sagittal slices of simulated temperature distributions for patients with fat layer b2 cmw
capacitive electrodes andwith conventional 70MHz radiative device (AMC-4). Themaximum te
the target region (Ptarget) is indicated for each distribution. Slices were taken approximately th
target region. Reprinted from open access reference [63].2) Tumor size – The applicatormust be capable to heat the entire target
volume. In case of superficial applicators, an applicator with thermal
effective field size (TEFS) that covers the complete target volume
should be used. The size of TEFS is often limited by the footprint of
the aperture. In case of phased arrays, the operational frequency in-
fluences the special resolution of power deposition and should be
carefully chosen. In case that the applicator cannot cover the whole
target volume, multiple abutting fields should be outlined to cover
the target entirely, and then administered sequentially.
3) Proximity to adjacent critical normal tissue structures – HT treat-
ment planning is recommended in cases where the tumor is adja-
cent to critical tissues or adjacent to metallic/breast implants.
Implants are not cooled with blood perfusion and metallic implants
concentrate electric currents, potentially giving rise to unwanted
local hot spots that can be treatment-limiting. Treatment planningith cancers in different sites (cervix, prostate, bladder and rectum) heated with 13.56MHz
mperature in all distributions is 44°C. The total power absorbed in the patient (Ptot) and in
rough the center of the patient. The contour in the temperature distributions indicates the
9M.M. Paulides et al. / Advanced Drug Delivery Reviews 163–164 (2020) 3–18is also recommended for superficial and intracavitary/interstitial HT
[73].When applying RF-capacitive heating, cautionmust be taken to
prevent unintended heating of the fat tissue layer. In deep HT, the
adaptive optimization algorithms that have been developed in re-
cent years are powerful tool to achieve high tumor temperatures
even in challenging cases [54,55].
2.3.5. Comparison to other techniques
Applicators based on RF/MW technology are currently the most
commonly used when treating cancer patients with HT. During the
last few years there has been a growing interest for using ultrasound
(US) to induceHT, due to its higher penetration depth andmm-scale fo-
cusing capabilities [74]. Initially developed to thermally ablate (N55 °C)
small tumors [75,76], focused ultrasound (FUS) can ablate up to ~16
mm tumors by focus steering, and larger tumors by sequentially ablat-
ing the whole volume. FUS for mild-to-moderate temperatures of
40–44 °C, i.e. HT, has been proven promising in small animal tumors
(b1.3cm3) [76–78], but application in humans is still undergoing clinical
trials [79–81]. Compared to US, RF/MW techniques have the highest po-
tential to cover and treat tumors larger than 4 cm and in regions near
the skin, bone structures or air cavities. A more detailed coverage of
the potential for FUS hyperthermia can be found in [81].
2.4. Treatment monitoring
Thermal dose monitoring is a critical instance of the HT treatment
that enables to control and evaluate in real-time the quality of the treat-
ment. The invasivemeasurements in tumor-related reference points are
still regarded bymany clinicians as a gold standard.Multiple sensors are
either placed to measure temperatures across the treated area, or cycli-
cally pulled through catheters tomap temperatures in invasively placed
catheters or across the skin surface (thermal mapping). Stationary
probes are typically used as references for real-time feedback power
control to maintain temperatures in the target between 40.0 and 42 °C
for 30–60 min, as is optimal for enhancing perfusion as well as thermal
sensitization, and simultaneously below 44.0 °C in healthy tissues to
avoid overheating. Often, manual intervention by the operator is
needed to trigger adjusting the power to keep temperatures within
the desired range. Techniques that are used to assess temperatures dur-
ing HT treatment include thermistors, fiber-optic probes and thermo-
couples [69,82].
Unfortunately, invasive thermometry approaches typically involve
the use of only a few monitoring positions, which often result in
under sampling of temperatures in areas with significant temperature
gradients [83]. Moreover, the insertion of intratumoral thermometers
may restrict the number of patients being treatedwith HT due to poten-
tial complications associated with the invasive procedure. The recent
trend in thermal dosimetry for deep-seated and regional HT is the use
of non-invasive techniques based on MR. However at this moment
this approach is not standard in the clinic and clinical trials on RF/MW
hyperthermia. Non-invasive techniques based on MR are described in
detail in chapter 4.
Besides temperature, other relevant clinical parameters to be moni-
tored include blood flow (units L/min) and blood perfusion rate (units
kg/s/m3 or mL/min/kg), where the latter reflects the blood perfusion
in themicrocirculation bed. Note that in response to heating, blood per-
fusion is upregulated by the body to reduce tissue temperature back to
the homeostatic set-point. Real-time measurement of the temperature
and/or perfusion enables to adjust the applied power to maintain the
desired temperature elevation. Chemotherapy benefits from HT due to
increased blood perfusion in tumors that is accommodated with in-
creased permeability of the tumor blood vessels, thus improving the
leakage of drugs where heating is occurring [84]. Monitoring blood per-
fusion and/or blood flow can be estimated based on dedicatedmeasure-
ments with invasive thermometry [85] but is currently commercially
only available for the Alba ON4000 superficial unit (Table 2) using
doppler techniques. Another approach to monitor blood perfusion isto use contrast enhanced (DCE) magnetic resonance imaging (MRI),
which has been used to predict response of locally advanced breast can-
cer patients to neoadjuvant chemotherapy and HT [86]. The contrast of
DCE-MRI distorts MR thermometry and good signal-to-noise imaging is
required, which is not readily available for EM applicators.
Finally, hyperthermia treatments are generally conducted without
anesthesia or sedation. This is critical for two reasons: 1) patients can
provide feedback about pain induced by hot spots, thus improving
safety profile of the treatment; and 2) anesthesia impairs normal ther-
moregulatory function (see e.g. [87]),which limits the ability to increase
blood perfusion as a response to higher therapeutic temperatures. The
exceptions are for whole body hyperthermia, which is conducted with
deep sedation or general anesthesia [43], and for hyperthermia treat-
ments in children, where mild to deeper sedation is provided to reduce
anxiety and restlessness [8].
3. Clinical applications of RF and MWmediated hyperthermia
HT has been successfully used in combination with radiation thera-
pies since the 70s. The pioneering work on cervical [100], breast [101],
head and neck cancer [102] has defined the basis for present protocols
and acceptance of hyperthermia. The most recent overview of random-
ized trials and metanalyses combining hyperthermia with radiation is
given in references [5,103]. Following a similar trend, adjuvant HT has
rapidly expanded its use to increase local drug delivery and local cyto-
toxicity of systemically administered chemotherapeutic agents. A com-
prehensive summary of trials primarily combining hyperthermia with
chemotherapy is however currently missing. Thus, this section summa-
rizes the clinical trials that studied the effect of HT as adjuvant to che-
motherapy (CT), or chemoradiation (CRT) if chemo-stimulation was
the goal, i.e., chemotherapy plus HT (CHT) and chemoradiation plus
HT (RCHT). In this section, we only included those trials where HT
was deliveredwith RF/MWdevices. The commercially available devices
used in these clinical trials are listed in Table 2, while details about other
devices no longer available are given as a footnote.
3.1. Bladder cancer
Colomboet al. conducted amulti-center randomized trial comparing
the use of mitomycin C alone and in combination with the Synergo in-
tracavitary MW device for the treatment of non-muscle invasive blad-
der cancer [104]. At 2-year follow-up, 83 patients were accrued and
the recurrence-free survival in the combined arm was significantly
higher: 82.9% (CHT) vs. 42.5% (CT). The long-term outcomes were re-
ported in 2011: 10-year disease-free survival (DFS) was 52.8% for CHT
vs. 14.6% for CT; and bladder preservation rates were 86% for CHT and
79% for CT [7]. The use of regional HT with intravesical mitomycin C
was analyzed in a pilot study (n = 18) with the external AMC 70 MHz
device using 1 or 2 rings of four waveguide antennas per ring. This de-
vice was the precursor of the commercially available Alba 4D. The
recurrent-free survival was 78% at 24 months without any grade 3 or
higher toxicities [105]. Another pilot study (n=45) analyzed the com-
bination of regional HT (BSD-2000 3D), radiation and chemotherapy
(cisplatin, 5-fluorouracil, carboplatin, or paclitaxel) to treat high-risk
T1 and T2 bladder cancer [106]. Grade 3 and 4 sequelae were reported
in 24% of the patients, but overall survival (80%) and bladder-
preserving rate (96%) at 3 years follow up were quite encouraging.
3.2. Sarcomas
In 2010, Issels et al. reported a phase III multi-center EuropeanOrga-
nization of Research and Treatment of Cancer (EORTC) trial in localized
high-risk-soft-tissue sarcoma. This was a large trial with 341 patients
randomized to receive a three-drug-regimen alone or with regional
HT using BSD-2000 equipment [107]. Treatment response was signifi-
cantly improved in the CHT group with 28.8% responders compared to
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prolonged survival rates in CHTwhen compared with CT alone: 10-year
survival of 52.6% vs 42.7% [6]. The results indicate that regional HT from
an RF array applicator combined with the three-drug-regimen can be
given safely with moderate and acceptable toxicity, accompanied by
significantly improved clinical response. Another clinical trial studied
the multimodality RCHT treatment using the Thermotron RF-8 device
combinedwith cisplatin and pinorubin as drugs [108]. Tumor shrinkage
was observed in 43 out of 44 patients (98%) and therewas recurrence in
only one patient. Of the 36 patients who presented M0 tumors (i.e., no
disease in distant sites), 30 were disease-free at final follow-up and 2
had no evidence of disease.
3.3. Head and neck cancer
Three randomized trials studied the effects of tri-modality RCHT vs.
conventional RCT for treating nasopharyngeal carcinoma [109–111].
Hua et al. used cisplatin +5-fluorouracil with an intracavitary 915
MHz device,2 Kang et al. used cisplatin only with external 915 MHz
radiators,3 and Zhao used cisplatin + paclitaxel with external RF capac-
itive 13.56 MHz HT.4 All studies showed significantly improved out-
comes with added RF/MW HT. Local control rates increased from
12.2% (RCT) to 19.2% (RCHT); 5-year survival increased from 7.9% to
18.4% with HT; 5-year progression-free survival increased 9.6% [109];
5-year DFS increased 30.8% [110]; and average DFS increased from
37.5 to 78 months [111]. Two of these studies evaluated complete re-
sponse (CR), reporting that the addition of HT increased CR from
81.1% to 98.6% in one study [109] and from 62.8% to 81.6% in the other
[110]. Quality of life (QoL) was assessed by Zhao et al. and patients
that received HT showed significantly improved QoL scores [111]. Fur-
thermore, Datta et al. performed a systematic review and meta-
analysis of RT + HT in the management of head and neck cancers
using RF/MW devices [102]. Although the role of CT was not included,
the authors highlighted that various phase I/II trials and preclinical stud-
ies have shown that a tri-modality therapy adding cisplatin with HT +
RT can achieve a synergistic effect that can translate into clinical efficacy.
3.4. Esophageal cancer
Three randomized studies demonstrated an advantage in the treat-
ment of esophageal cancer when adding HT to CT or RCT [112–114].
In one of these studies, 53 patients were treated with HT using the
intraluminal Endoradiotherm 100A device5 (13.56 MHz internal elec-
trode + external planar electrode) and histopathologic response was
significantly improved in the tri-modality arm: 66.7% vs. 38.5% [112].
In addition, 70.4% of patients treatedwith RCHT stated an improvement
in swallowing capability, while only 7.7% of patients reported improve-
ment in the RCT group. In a follow-up study [113], an additional 40 pa-
tients were randomized between CT and CHT yielding a favorable
histopathologic response for the dual-modality CHT treatment (41.2%)
vs. CT alone (18.8%). A third randomized trial used an intraluminal
915 MHz microwave applicator (model undisclosed) for heating,
which reported a 3-year survival rate of 42.4% in the RHT group vs.
24.2% for RT alone [114]. Kuwano et al. conducted the largest clinical
trial to date (n = 243) studying the effects of intraluminal RF HT com-
bined with chemotherapy and irradiation on esophageal cancer overall
survival (OS) [115]. Both pathological CR (8.4% vs. 19.1%) and 5-year OS
(13.7% vs. 22.3%) where significantly higher in the RCHT group, when
compared with the standard of care. More recent single-arm studies of
adjuvant heat have further validated extended survival in esophageal2 WE2102-A MW hyperthermia system, Yuan De Biomedical Engineering, Beijing
3 Pingliang 778WR-L-4MWhyperthermiamachine, Sunostick Medical Technology Co.,
Ltd., London, UK
4 HG-2000-type RF applicator, Zhuhai Hokai Medical Instruments, Guangzhou, China
5 Endoradiotherm 100A, Olympus Optical Co. Ltd., Japancancer patients with 5-year OS of 50.0% (n = 24) [116] and 3-year OS
of 42.5% (n = 50) [117]. Toxicities were reported to be tolerable and
limited to grade 2 or 3 in all studies. Nakajima et al. [116] used the
Endoradiotherm 100A device and Sheng et al. [117] used a RF capacitive
heating device based on a spiral strip applicator design (unknown
frequency).6
3.5. Rectal cancer
In a retrospective study of 106 patients treated with 5-fluorouracil
and radiation with/without hyperthermia (BSD-2000 system), the
pathological CR (pCR) in the RCT group was seen only in 6.7% of pa-
tients, whereas in the RCHT group a pCR of 16.4% was achieved [118].
These results were even more impressive when analyzing the subset
of patients that received four or more HT treatments, who presented a
significantly higher pathological CR of 22.5%. Despite these encouraging
results in terms of pCR, translation to improved local control and/or
overall survival still needs to be determined. In a retrospective trial of
neoadjuvant RCT with regional HT using the BSD-2000 system, Maluta
et al. observed a local control rate of 100% at 5-year follow-up for all pa-
tients who achieved pSCR (18 of 76) [119]. In two more recent phase II
trials, the use of capecitabine, radiation and capacitive HTwas analyzed
yielding impressive results. Barsukov et al. accrued 64 patients and used
an RF capacitive 14 MHz device,7 adding oxaliplatin and metronidazole
to a capecitabine regimen: the 2-year OS and DFS was 91% and 83%, re-
spectively [120]. Using only capecitabine and an intracavitary 433 MHz
Yachta-4 device, Rasulov et al. achieved in 81 patients a 97% 3-year OS
and 85% 2-year DFS regimen [121] in a single arm study.
3.6. Anal cancer
The clinical benefit of adding intracavitary HT (customized 433MHz
dipole antenna) to a RCT regimenwas explored in a randomized trial in
anal cancer patients [122]. After a 5-year follow up, 68.0% of the patients
in the CT arm had sphincter preservation, whereas 95.8% of the patients
in the RCHT arm preserved their anorectal function and avoided perma-
nent colostomy. In the HT arm, locoregional recurrence was signifi-
cantly higher (32.0% vs 4.2%), and the local recurrence-free survival
time was also significantly higher (59.7% vs 50.4%). A more recent
non-randomized trial compared RCT with and without deep regional
HT (BSD-2000 3D and BSD-2000 3D/MR) in patients with anal cancer
[123]. The chemo regimen included 5-fluorouracil and mitomycin C.
After 5 years follow-up, disease-free (89.1 vs. 70.4%), local recurrence-
free (97.7 vs. 78.7%), colostomy-free (87.7 vs. 69.0%), and overall sur-
vival rates (95.8 vs. 74.5%) were significantly better for the RCHT
group. Grades 3–4 toxicities were comparable except for
hematotoxicity (66 vs. 43%) and telangiectasia (38.0 vs. 16.1%) that
were higher in the RCHT group.
3.7. Lung cancer
Shen et al. randomized 80 patients to gemcitabine and cisplatin with
and without heat administrated by the capacitive RF regional heating
using the HY7000 device [124] for the treatment of non-small cell
lung cancer (NSCLC). Although therewas no significant difference in re-
sponse rates, the clinical benefit response (a clinical index usedwith in-
curable tumors to assess improvement in quality of life) was
significantly higher in the CHT group: 82.5% versus 47.5%. Using the
same trial modality and heating device, Yang et al. evaluated retrospec-
tively the medical records of 93 patients with advanced NSCLC [98],
where the overall response rate of pleural effusions was significantly
better in the CHT (81.2%) group than in the CT group (40.0%). The pa-
tients in the CHT group also presented lower incidence rate ofweakness6 HRL-001, Jilin Maida, China
7 Yagel, JSC MC SEZ Istok, Fryazino, Russia
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77.8%) than in the CT group. No significant differences were shown in
the objective tumor response and survival rates. Wang et al. [125] per-
formed a clinical study with the NRL-001 RF regional heating device
using the same drugs (gemcitabine and cisplatin) in 119 patients with
advanced NSCLC, but adding a third treatment armwith radiation. A re-
markable curative ratewas achievedwith tri-modality treatment: 90.7%
(RCHT) vs. 72.8% (RCT) and 62.2% (RT). Although toxicity increased in
the RCHT group, it was reported to be tolerable or readily alleviated
with short-term symptomatic treatment. Overall, patients treated in
the tri-modality arm achieved significant higher quality of life and im-
provement in alleviation of tumor oppression syndrome.
3.8. Other cancers
Datta et al. performed a networkmeta-analysis (NMA) of four differ-
ent treatment regimens for cervical cancer: RT, RHT, RCT, and RCHT
[126]. The pairwise comparison of various groups showed that RCHT
was the best option for both CR and patient survival. A wide range of
RF/MW heating devices were used for these studies including regional
heating with either capacitive or radiative RF systems or intracavitary
heating with custom-built coaxial applicators. In 1984, the use of 2.45
GHz local irradiation using an intracavitary devicewas explored in com-
binationwith a bleomycin+mitomycin C regimen to treat vaginal can-
cer. The positive response rate increased to 59.5% compared with 19.2%
when using CT alone. Two pilot studies explored the use of thermally
enhanced drug delivery using low temperature liposomal doxorubicin
in heavily pretreated patients with chest wall recurrences [13]. Heating
was achieved with BSD-500 equipment that uses multiple microwave
applicators that heat up to 3 cm deep. These trials demonstrated safety
and objective responses in heavily pretreated patients with chest wallTable 3
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with cytokine-induced killer cells.recurrence. A recent systematic review compared 14 phase I/II clinical
studies (n=395) on locally advanced and/ormetastatic pancreatic can-
cer patients that used adjuvant HT [127]. Patients were treated with re-
gional capacitive/radiative RF HT (n=189), intracavitary MWHT (n=
39) or whole-body HT (WBH) using infrared radiant heat devices (n=
20), in combination with radiation, chemotherapy or both. A control
group was included in six studies that showed a longer OS in the HT
groups than in the control groups: 11.7 vs. 5.6 months. In three studies
with a control group, the overall response rate was also improved for
the HT groups: 43.9% vs. 35.3%. Finally, the BSD applicators Sigma-30/
40/60 were used in combination with CT to treat children with refrac-
tory or recurrent non-testicular malignant germ-cell tumors that failed
a standard cisplatin regimen [8]. The new chemo regimenwas based on
a combination of cisplatin, etoposide, and ifosfamide, also known as PEI
regimen. The treatment also included surgical resection or radiation to
patients with incomplete tumor resection. Of the 35 patients who had
sufficient data available for response assessment, 86% had an objective
response to treatment and the 5-year OS was 72%. This multimodal
treatment using regional HT proved to successfully treat children and
adolescents with refractory or recurrent malignant non-testicular
germ-cell tumors.
3.9. Summary of clinical trials
The use of MW/RF HT in combination with different chemotherapy
regimens has proved its merit and warrants further investigation.
Table 3 lists all active Phase I/II, Phase II, and Phase III trials that are ex-
ploring the use of MW/RF HT, either radiative or capacitive, in combina-
tion with chemotherapy or immunotherapy regimens. We used these
criteria and performed a search in the ClinicalTrials.gov using “cancer”
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Fig. 3. Hyperthermia Treatment Planning (HTP) workflow. Reprinted from [54].
12 M.M. Paulides et al. / Advanced Drug Delivery Reviews 163–164 (2020) 3–18AND hyperthermia” under “Other terms” on March 16, 2020. This
search yield 241 clinical trials, of which the vastmajoritywere either re-
lated to hyperthermic chemoperfusion methods or included some syn-
onymous of hyperthermia (fever, febrile, temperature elevation, or heat
treatment) not related to a cancer treatment. The other trials excluded
from the list used focused ultrasound and laser hyperthermia.
4. Potential for RF andmicrowavemediated hyperthermia and drug
delivery
Current RF/MW hyperthermia treatments are driven by qualitative
patient complaints and are limited by very few measured temperature
points. In order to make a more complete and quantitative assessment
of the heated treatment field, there are two avenues that can extend
our knowledge of the applied energy (SAR in W/kg) and temperature
distributions in tissue: computer simulations and magnetic resonance
(MR) thermometry. Computer simulations use numerical methods 3D
patient-specific anatomical models to generate SAR and temperature
maps. The simulations are typically used to generate a pre-treatment
plan, but the same tools are also used for online treatment guidance.
Such simulation-guided HT uses a feedback optimization scheme that
is updated with the signals applied to the antennas, the measured tem-
peratures, and feedback from patients, so that treatment settings are
adapted in real-time to optimize the treatment delivery [85]. The most
advanced thermal assessment for HT is MR thermometry (MRT),
which provides 3D temperature maps superimposed with the patient
anatomy [128]. Ishihara et al. developed the framework for the most
used method to calculate MRT, the proton resonance frequency shift
method [129]. This method allows to obtain MRT maps from MR
phase data [130]. These maps are currently obtained about every 10
min or 15 min and only now are starting to be used in HT treatment
guidance. The last possible iteration of MR-HT guidance is to combine
simulations with MRT, thus providing the ultimate level of dosimetry
before, during and after treatment. These tools facilitate rigorous tem-
perature control and simulation-based heating adjustment possibilities,
which is a requirement for optimal enhancement of drug delivery of
conventional systemic chemotherapy and/or temperature mediated
drugs [74].
4.1. Simulation-guided hyperthermia
Clinical application of HT is usually delivered after performing
patient-specific HT treatment planning (HTP) [54,55]. The latest ad-
vancements on HTP have been driven by enhanced computer capabili-
ties and recent advancement in computational algorithms. The HTP
process begins by acquiring 3D images of the patient anatomy compris-
ing the treatment volume, obtained from computed tomography and/or
magnetic resonance imaging (MRI). The following step is to delineate
the different tissues, where the required number of tissues and the
level of detail of the delineation depends on the desired accuracy,
which varies for each application. For deep HT, the tissues usually seg-
mented include muscle, fat, bone and internal air [131]. Head andneck treatments involve more critical structures that 11 additional tis-
sues are discriminated [132]. The end result is a patients-specific
model that will feed the simulation phase.
In the next step, the patient virtual model is imported into a
multiphysics simulation software that already has the virtual HT appli-
cator design. Then, dielectric and thermal properties are assigned to
each tissue, including physiological parameters like blood perfusion
rate (units of kg/s/m3) and metabolic heat generation rate (units of
W/m3). The final step is then to perform the SAR and temperature sim-
ulations and optimize the antenna parameters to target the patient
tumor. The Pennes bioheat method is commonly used to compute the
temperature profile in the tissue [33]. The position of the patient
model relative to the applicator will be documented and should be
reproduced during the actual treatment to deliver the planned opti-
mized treatment. Fig. 3 shows the Schematic workflow for EM-HTP,
using head and neck hyperthermia as an example.
The patient-specific HTP is a robust tool for treatment decisionmak-
ing, i.e., whether to treat or not, since it facilitates evaluating the ability
to heat a specific tumor and to identify potential hotspots before
performing the treatment. In addition, HTP can help physicians to con-
duct the treatment and perform real-time adaptations to the treatment
to respond to patient complaints. Besides treatment planning and opti-
mization, HTP is also a valuable tool for the development of medical de-
vices, training of HT personnel, and post-treatment dosimetry to
evaluate the delivered treatment strategy. The only commercial pack-
age for HTP currently available is HyperPlan (Sennewald
Medizintechnik, Munich, Germany), which allows to optimize treat-
ment settings using electromagnetic and thermal simulators for the
BSD-2000 applicator series. More general electromagnetic and thermal
solvers like Sim4Life (ZMT Zurich MedTech AG, Zurich, Switzerland),
CST Studio Suite (Dassault Systèmes, Vélizy-Villacoublay Cedex,
France) and ANSYS (Canonsburg, Pennsylvania, US) are also used to
perform electromagnetic and thermal simulations.
HT treatment guidance using real-time simulations has greatly
benefited from the introduction of various HTP platforms, including
VEDO, the visualization tool for electromagnetic dosimetry and optimi-
zation [133], and Plan2Heat [134]. In a retrospective analysis of treat-
ment reports of 35 patients treated with deep HT controlled by
extensive treatment planning, it was demonstrated, that HTP is able to
provide a global indication of the regions where hotspots during treat-
ment will most likely occur [135]. A recent advancement of HTP, is
patient-complaint guided steering, where heating is steered from a re-
gion of complaint by adding constraint factors for that region. Ampli-
tude and phase of each individual element can be re-optimized to
maintain the optimum tumor dose while minimizing the heating in
the area of complaint [131,133,134].
4.2. Mr-guided hyperthermia
HT treatments are monitored using a limited number of superficial
or invasive thermometry probes using stationary measurements or
measuring along the implanted catheter track. In time, MRI has
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modality, i.e., magnetic resonance thermometry (MRT) [136]. MRT pro-
vides the option of 3D non-invasive temperature monitoring of the full
treatment region, including tumor and surrounding tissues. Hence, MR-
HT hybrid systems can operate within the MR bore to facilitate MRT
during treatment. Besides providing assurance of effective steering,
the 3D temperature data is also used to evaluate hotspots, i.e., regions
that are getting too hot in healthy tissue. The operator can then adjust
the heating patterns to protect healthy tissue and avoid patient discom-
fort and pain that, if unaccounted for, may lead to unwanted side effects
such as burns. An example of MR-guided hyperthermia is illustrated in
Fig. 4.
Besides temperature monitoring, MRI is being explored to capture
other patient parameters relevant for HT, including electrical tissue
properties [137], diffusion [138] and blood perfusion [139,140]. At the
moment, HTP simulations are based on parameters from literature,
which are typically the result of an average of limited data and mea-
sured ex vivo. Thus, acquiring of the 3D patient-specific properties, to-
gether with accurate and reproducible patient positioning, makes the
use of MR a very attractive addition to HT treatments. Finally, MR can
also accurately reproduce changes of body shape due to pressure of
thewater bolus for amore accuratemodelling of tissue position relative
to the applicator [141]. To this date, MR-HT systems are only available
for deep HT, and it use has been reported for the treatment of pelvic
and extremities tumors (BSD2000-3D/MR) [128,142,143] and lower ex-
tremities (MAPA) [144–146]. An extensive review of clinical and pre-
clinical MR-HT applicators can be found in [147,148].
MR can also be a relevant tool to validate mathematical models,
which are being evaluated to predict the effect of HT and specific che-
motherapeutic agents. A recent studywith heat-shock responsemodels
support the belief that the combination of HT with bortezomib, a clini-
cally approved proteasome inhibitor, increase therapy efficacy [149].
Mathematical models are also being developed to predict the spatial
drug delivery profile of temperature sensitive liposomes [150,151].
The combination of improved modelling approaches, more powerful
and faster computations and real-time monitoring will accelerate the
evolution of HTP leading to improved delivery of clinical HT treatments.
Some of the currentmain limitations ofMRT include the high cost of the
MR system and difficulty in maintaining stable temperature measure-
ments over long durations ~60–90min due tomotion artifacts (respira-
tory motion, organ motion and air travelling), and magnetic field drift
artifacts [130,152].Fig. 4. Example of MR guided hyperthermia. The left panel shows the T-1 imagewith the deline
treatment. Courtesy of Dr. Sennewald Medizintechnik GmbH (Germany).The advancement of MR monitoring will facilitate the optimization
of temperature kinetics of drugs to deliver a local treatment. Automatic
MR-based feedback loop control are currently being evaluated to adapt
the hyperthermia treatment for a patient specific session [147]. This
aims to optimize the treatment with the objective of delivering the
best thermal dosewhile preventing the generation of treatment limiting
undesired hotspots. Hence, MR-guided HT can play an unprecedented
role in localizing heat that can be tailored to temperature sensitive
nanocarriers loaded with a chemo- or immunotherapy payload. This
multimodality treatment can lead to significantly more targeted drug
delivery and reduce side effects, which can facilitate increasing the
number of patients treated with thermochemotherapy or
thermoimmunotherapy.
5. Future outlook
RF and MW HT devices have been the golden standard for clinical
studies using thermal therapies for multi-modality cancer treatment.
Yet, thermal dose-effect studies indicate that an even higher therapeutic
outcome is achievable when higher temperatures are reached. In this
review, we report on devices that use higher frequency EM waves, i.e.
MW and RF, which are under development and/or being translated
into the clinic [59,71,153–156]. These devices can induce a smaller
heat focus then current RF based systems [157,158], which can
be dynamically adjusted to conformal heating of irregular target
regions [159].
Target conformal heating requires tight dose monitoring to ensure
that the heat focus is precisely aimed and maintained at the target re-
gion. Hence, researchers are investigating improved approaches for
(real-time) and 3D dosimetry. As explained, treatment planning has
matured and is being studied for pre-treatment planning as well as for
real-time guidance. In addition, following an earlier clinical adoption
in (FUS-induced) ablation therapy [160,161], MRT is slowly starting to
make its mark also in HT. The developments in simulation and MRT
guided treatment are expected to reinforce each other since MRT
forms the tool required to validate treatment planning in 3D. In addi-
tion, validated treatment planning simulations not only provide the
tool for guiding treatment but also provides the tool to design better ap-
plicators, create treatment and quality assurance guidelines, perform
better training and develop new treatment approaches. Following
these developments, and in view of cost and complexity of treatment,
we expect that two distinct approaches will appear that will co-exist:ated sarcoma on the leg, the right panel shows theMR-thermometrymap at the end of the
14 M.M. Paulides et al. / Advanced Drug Delivery Reviews 163–164 (2020) 3–181) the simulation-adaptive HT approach that provides a relatively low-
costmeans to stimulate a range of cytotoxic drugs and 2) a personalized
high-precision MR-adaptive approach based on advanced MR-guided
HT.
Simulation-adaptive HT will be based on HT with RF or MW tech-
niques and will exploit our increasing knowledge of thermoregulation.
This knowledgewill be included into advanced treatment planning soft-
ware tools to pre-plan the treatment and perform real-time guidance.
Monitoring will be based on a combination of interstitial, intraluminal
and/or intracavitary thermometry with 3D treatment planning. To im-
prove the effectiveness of the combination of HT and drugs, this line
would strongly benefit from advancing our knowledge on temperature
dependent perfusion to enable optimizing the temperature distribution.
This approach already exists in the academic setting and will be im-
proved to speed-up the learning curve for new clinics entering this
field. In addition, approaches like automatic segmentation will reduce
the time-consuming labor of treatment planning and the required ex-
pertise, thus facilitating smooth dissemination of simulation-adaptive
HT to non-academic clinics.
The most advanced high-precision MR-adaptive HT, will probably
remain an approach for academic centers in the upcoming decade.
The utility of MR-adaptive HT is still in its infancy and its development
will be strongly correlated with progress in MRT, especially in regions
where measurements are affected by respiratory, cardiac or peristaltic
driven motion or other actions that imply organ/tissue movement
such as swallowing. Hence, MRT guided HT crucially depends on
motion-robust MRT at an accuracy better than 1 °C [162–164] since
the aim is to increase temperature by only 3–7 °C. The maximum
achievable accuracy of MRT is dictated strongly by the time required
to capture a full MRT scan. For anatomical MR imaging, averaging of
multiple measurements is usually used to obtain the required signal-
to-noise ratio (SNR) per scan [165]. This approach is not possible for
MRT since averaging effects (over a single scan) should be minimized
as they will increase motion artifacts and reduce the temporal accuracy
of the temperature measurements. In this respect, first generation MR-
HT systems are using the body coil of the MR scanner leading to a lim-
ited SNR performance [166]. More recent approaches use dedicated im-
aging coils nearby the skin of the patient for higher SNR as well as
exploitation of faster, i.e. parallel, imaging approaches, which are
based on the spatial differences between receive coil sensitivities. Re-
cent investigation have also explored different MR excitation schemes
to accelerate image reconstruction in 2D and 3D [167,168], and tomon-
itor temperature changes in fatty and aqueous tissue simultaneously
[169]. The actual improvement of these methods for the hyperthermia
application are yet to be validated in the clinical setting.
MRI has other features of which the utility for controlling HT is cur-
rently being investigated. Firstly, MRI provides anatomy contrast that is
unprecedented in the imaging field. Hence, MRI is optimally suited to
verify patient positioning inside the applicator, as basis for adapting
treatment planning in real-time and to monitor the tumor regression/
progression during the course of therapy. In addition, a range of MRI
techniques exist, with or without contrast enhancement, to visualize
physiological properties like blood perfusion during therapy. When ap-
plied in conjunction with chemotherapy, this approach might enable
feedback-controlled image-guided drug delivery approaches. Hence,
MR guided therapy is especially beneficial when used to sensitize for
drugs and/or improve delivery homogeneity.
MR-guidance may play another important role when using
thermosensitive liposomes [74]. These liposomes can be filled with a
mix of MR contrast fluid and drugs for calibrating the MRT [170] or for
close drug delivery monitoring. Note that the validity of the latter ap-
proach for monitoring drug delivery is determined by the similarity in
diffusion depth from vessel into the tissue of themolecules for monitor-
ing and delivery. Note also that MRT accuracy can be affected by para-
magnetic contrast agents [171]. Still, recent studies have shown that,
at ultra-high-field MRI (≥7 T), visualizing metabolism is possible tomore precisely track tumor activity [172]. This approach can even be en-
hanced when expanding the imaging to more multi-nuclei, i.e., using
not only hydrogen but also phosphorus atoms, which provides informa-
tion similar to positron emission tomography (PET) and may also im-
prove MRT [173]. Pre-clinical evidence suggests that this may strongly
enhance sensitivity for aberrant metabolism, which is known to corre-
late with tumor aggressiveness. However, whether MR-HT devices can
deliver on this potential is currently unknown. Still, there are many op-
portunities for MR-adaptive HT using the plethora of anatomical, phys-
iological and metabolic MRI contrasts. The MR-guided RF and MW HT
devices currently under development provide solid bases to study the
benefit of all of these approaches independently, as well as combined.
In summary, RF techniques are usually used when HT is combined
with chemotherapy. The current level of quality and success of the de-
scribed clinical trials provides a solid basis since they showed signifi-
cantly improved therapeutic results. In contradiction to radiotherapy
with HT, thermal dose-effect studies have yet not been conducted so
the optimum temperature (range) for application of hyperthermia is
yet to be determined. In addition, not only temperature but also perfu-
sion may well be highly important to assess HT effectiveness. In this re-
spect, the advent of novel MR-guided devices provides many new
perspectives, which will help to elucidate thermal or perfusion dose-
effect relations. Integrated device and coil design, aswell as newheating
devices and temperature / perfusion measurement strategies should be
developed to enable highly controlled application of HT. Given recent
progress in these topics, combined with the advancements on temper-
ature mediated drugs, we expect that the upcoming decade will bring
breakthroughs in our knowledge, leading to optimized HT approaches
for cancer patients.
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